Drug intelligence / Profile preview

Niaoshi Gandandan Granules

Development stage: Unknown
Lead developer: Boji Pharmaceutical Technology
Administration: Oral

Overview

Niaoshi Gandandan Granules is a Traditional Chinese Medicine (TCM) granule formulation under development for the treatment of chronic cholecystitis, particularly in patients presenting with the liver-gallbladder damp-heat pattern. The drug is developed by Guangzhou Boji New Drug Clinical Research Center and is currently being evaluated in Phase II clinical trials in China. The therapeutic focus is on relieving abdominal pain, improving gallbladder ultrasound parameters, and reducing the recurrence of symptoms or the necessity for gallbladder surgery.

Other names: 尿石肝胆丹颗粒

Beyond the preview

Go deeper on Niaoshi Gandandan Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Niaoshi Gandandan Granules.

Explore the full profile